

<10804389>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005
NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
(ROSPATENT) added to list of core patent offices covered
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS
National Meeting on March 13, 2005
NEWS 20 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADOC
NEWS 21 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 22 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 23 MAR 02 GBFULL: New full-text patent database on STN
NEWS 24 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 25 MAR 03 MEDLINE file segment of TOXCENTER reloaded

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN

<10804389>

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:36:12 ON 07 MAR 2005

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 08:36:33 ON 07 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 4, 2005 (20050304/UP).

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'REGISTRY' ENTERED AT 08:36:47 ON 07 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 MAR 2005 HIGHEST RN 842949-55-7
DICTIONARY FILE UPDATES: 4 MAR 2005 HIGHEST RN 842949-55-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10804389.str

<10804389>



chain nodes :

16 24 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

6-7 8-16 10-24 24-25

ring bonds :

1-2 1-6 2-3 2-12 3-4 3-15 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 13-14 14-15

exact/norm bonds :

2-12 3-15 6-7 7-8 7-11 8-9 8-16 9-10 10-11 10-24 12-13 13-14 14-15 24-25

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

G2:O,S

G3:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 24:CLASS 25:CLASS


L1 STRUCTURE UPLOADED

=> D

L1 HAS NO ANSWERS

L1 STR

<10804389>



G1 C,N
G2 O,S
G3 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 08:37:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6124 TO ITERATE

16.3% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 117789 TO 127171
PROJECTED ANSWERS: 1 TO 270

L2 1 SEA SSS SAM L1

=> S L1 FULL
FULL SEARCH INITIATED 08:37:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 123369 TO ITERATE

100.0% PROCESSED 123369 ITERATIONS 163 ANSWERS
SEARCH TIME: 00.00.01

L3 163 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 161.33 161.60

FILE 'CAPLUS' ENTERED AT 08:37:29 ON 07 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

<10804389>

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2005 VOL 142 ISS 11
FILE LAST UPDATED: 6 Mar 2005 (20050306/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L3



L4 5 L3

=> D IBIB ABS HITSTR TOT

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:681569 CAPLUS
DOCUMENT NUMBER: 141:207197
TITLE: Preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.
INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara Prasad Venkata Nagendra; Jiao, Wenhua
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069245	A1	20040819	WO 2004-IB231	20040127
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-445909P P 20030207
OTHER SOURCE(S): MARPAT 141:207197
GI



AB Title compds. I [A = O, NH, S; B = COR1, CSR1, heterocyclo, etc.; R1 = H, alkyl, cycloalkyl, etc.; either D is N, E is C, and F = CH when "----" is a bond, or D = CH, E = N, and F = CH2 when "----" is absent (sic); P = tricyclic ring with provisos] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of hydrazine and dimethylaminomethylene II afforded oxazolidinone III in 60% yield. In *H. influenzae* (HI3542) min. inhibitory concentration (MIC) assays, 8-examples of compds. I exhibited MIC values ranging from 4-64 µg/mL, e.g., the MIC value of oxazolidinone III was 8 µg/mL. Compds. I are claimed useful for the treatment of bacterial infections.


IT **741253-96-3P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 741253-96-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[2-[(dimethylamino)methylene]-1,2,4,5-tetrahydro-3,3-dioxido-1-oxo-3-benzothiepin-7-yl]-2-oxo-5-oxazolidinyl)methyl]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 740842-28-8P 741253-73-6P 741253-74-7P
741253-75-8P 741253-76-9P 741253-78-1P
741253-79-2P 741253-80-5P 741253-81-6P

<10804389>

741253-82-7P 741253-83-8P 741253-84-9P
741253-85-0P 741253-86-1P 741253-87-2P
741253-88-3P 741253-89-4P 741253-92-9P
741253-93-0P 741253-95-2P 741253-98-5P
741254-00-2P 741254-01-3P 741254-02-4P
741254-03-5P 741254-04-6P 741254-05-7P
741254-06-8P 741254-07-9P 741254-08-0P
741254-09-1P 741254-10-4P 741254-11-5P
741254-12-6P 741254-13-7P 741254-14-8P
741254-15-9P 741254-16-0P 741254-17-1P
741254-18-2P 741254-19-3P 741254-20-6P
741254-21-7P 741254-22-8P 741254-23-9P
741254-24-0P 741254-25-1P 741254-26-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of N-substituted tricyclic oxazolidinones as antibacterial
agents.)

RN 740842-28-8 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 741253-73-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4,5-dihydro-2-methyl-1H-[1]benzoxepino[4,5-d]imidazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741253-74-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-2-(trifluoromethyl)-1H-[1]benzoxepino[4,5-d]imidazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)

<10804389>


Absolute stereochemistry.



RN 741253-75-8 CAPLUS

CN Acetamide, N-[[(5S) -3-(4,5-dihydro-2-phenyl-1H-[1]benzoxepino[4,5-d]imidazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741253-76-9 CAPLUS

CN Acetamide, N-[[(5S) -3-(4,5-dihydro-2-methyl[1]benzoxepino[5,4-d]thiazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741253-78-1 CAPLUS

CN Acetamide, N-[[(5S) -3-(2-amino-4,5-dihydro[1]benzoxepino[5,4-d]thiazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741253-79-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4,5-dihydro-2-phenyl[1]benzoxepino[5,4-d]thiazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741253-80-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-2-(4-pyridinyl)[1]benzoxepino[5,4-d]thiazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741253-81-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-2-(4-methoxyphenyl)[1]benzoxepino[5,4-d]thiazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741253-82-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741253-83-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4,5-dihydro-1-methyl-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741253-84-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-1-(2,2,2-trifluoroethyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741253-85-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-1-(2-hydroxyethyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 741253-86-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[1-(3-chlorophenyl)-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 741253-87-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[1-(cyanomethyl)-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741253-88-3 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-1-oxo-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741253-89-4 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-1-oxo-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741253-92-9 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741253-93-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(dimethylamino)methylene]-1,2,4,5-tetrahydro-5-oxo-3-benzothiepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741253-95-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-(6,7-dihydro[3]benzothiepin-1,2-d]pyrimidin-9-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741253-98-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-(6,7-dihydro-5,5-dioxido[3]benzothiepin-1,2-d]pyrimidin-9-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741254-00-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-(methylthio)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-01-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[8-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-02-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-(4-morpholinyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741254-03-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-(4-fluorophenyl)-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 741254-04-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-(4-pyridinyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-05-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4,5-dihydro-3-phenyl-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741254-06-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-(5-isoxazolyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-07-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-(methylamino)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-08-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-(ethylamino)-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741254-09-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-(phenylamino)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-10-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-[[[4-methoxyphenyl)methyl]amino]-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-11-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3-amino-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741254-12-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3-ethyl-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-13-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-3-(5-methyl-3-isoxazolyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-14-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-(2-furanyl)-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741254-15-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-(2-amino-4,5-dihydro[1]benzoxepino[5,4-d]thiazol-8-yl)-2-oxo-5-oxazolidinyl]methyl]-, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HBr

RN 741254-16-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-2-(methylamino)[1]benzoxepino[5,4-d]thiazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HBr

<10804389>

RN 741254-17-1 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(4-pyridinylmethylene)-1-benzoxepin-8-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741254-18-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(dimethylamino)methylene]-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741254-19-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4,5-dihydro[1]benzoxepino[4,5-d]isoxazol-8-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-20-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4,5-dihydro-2-methyl-2H-[1]benzoxepino[5,4-

<10804389>

c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-21-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-(2-ethyl-4,5-dihydro-2H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-22-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-(1-ethyl-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-23-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-2-(phenylmethyl)-2H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

<10804389>


Absolute stereochemistry.



RN 741254-24-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-1-(phenylmethyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-25-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-2-(2-phenylethyl)-2H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-26-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4,5-dihydro-1-(2-phenylethyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<10804389>



IT 741254-27-3P 741254-38-6P 741254-39-7P
741254-40-0P 741254-41-1P 741254-55-7P
741254-56-8P 741254-57-9P 741254-58-0P
741254-60-4P 741254-61-5P 741254-62-6P
741254-63-7P 741254-64-8P 741254-65-9P
741254-66-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 741254-27-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4-bromo-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-38-6 CAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




<10804389>

RN 741254-39-7 CAPLUS

CN Butanoic acid, [(5R)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-40-0 CAPLUS

CN 2-Oxazolidinone, 5-[[[(methanesulfonyl)oxy]methyl]-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-41-1 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-55-7 CAPLUS

<10804389>

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-56-8 CAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-57-9 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-58-0 CAPLUS

CN 1-Benzoxepin-4-carbodithioic acid, 8-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3,4,5-tetrahydro-5-oxo-, methyl ester (9CI) (CA INDEX NAME)

<10804389>


Absolute stereochemistry.



RN 741254-60-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(4-fluorobenzoyl)-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-61-5 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(4-pyridinylcarbonyl)-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-62-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-(4-benzoyl-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

<10804389>


Absolute stereochemistry.



RN 741254-63-7 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-4-(5-isoxazolylcarbonyl)-5-oxo-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-64-8 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(1-oxopropyl)-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-65-9 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-4-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 741254-66-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:681568 CAPLUS

DOCUMENT NUMBER: 141:190784

TITLE: Preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.

INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara Prasad Venkata Nagendra; Pettersson, Martin Youngjin; Lall, Manjinder Singh; Hagen, Susan Elizabeth; Boyer, Frederick Earl, Jr.

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069244	A1	20040819	WO 2004-IB209	20040127
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,			

<10804389>

MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US 2004224939

A1

20041111

US 2004-773588

20040205

PRIORITY APPLN. INFO.:


US 2003-445957P

P 20030207


OTHER SOURCE(S):

MARPAT 141:190784


GI



I



II



III

AB Title compds. I [A = O, NH, S; B = COR1, CSR1, heterocyclo, etc.; R1 = H, alkyl, cycloalkyl, etc.; either D is N, E is C, and F = CH when "----" is a bond, or D = CH, E = N, and F = CH2 when "----" is absent (sic); P = bicyclic ring, e.g., benzo[b]cycloheptanones, homochromanones, homothiochromanones, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, CrO3/Ac2O mediated oxidation of benzocycloheptane II, e.g., prepared from 1-benzouberone in 5-steps, afforded oxazolidinone III in 14% yield. In H. influenzae (HI3542) min. inhibitory concentration (MIC) assays, 15-examples of compds. I exhibited MIC values ranging from 2->64 µg/mL, e.g., the MIC value of oxazolidinone III was 8 µg/mL. Compds. I are claimed useful for the treatment of bacterial infections.

IT 444587-84-2P 740842-25-5P 740842-26-6P

740842-28-8P 740843-12-3P 740843-13-4P

740843-14-5P 740843-15-6P 740843-18-9P

740843-19-0P 740843-20-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.)

RN 444587-84-2 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 740842-25-5 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-26-6 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,1-dioxido-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-28-8 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


<10804389>



RN 740843-12-3 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzoxepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-13-4 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzoxepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740843-14-5 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 740843-15-6 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-18-9 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-19-0 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<10804389>

RN 740843-20-3 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 740842-67-5P 740842-68-6P 740842-70-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.)

RN 740842-67-5 CAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-68-6 CAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,1-dioxido-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 740842-70-0 CAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:609963 CAPLUS

DOCUMENT NUMBER: 141:140424

TITLE: Preparation of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as antibacterial agents

INVENTOR(S): Thomas, Richard Charles; Poel, Toni-jo; Barbachyn, Michael Robert; Gordeev, Mikhail Fedor; Luehr, Gary W.; Renslo, Adam; Singh, Upinder; Josyula, Vara Prasad Venkata Nagendra

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 169 pp., Cont.-in-part of U.S. Ser. No. 373,286.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.

KIND


DATE

APPLICATION NO.

DATE

<10804389>

US 2004147760	A1	20040729	US 2003-646440	20030822
US 2004044052	A1	20040304	US 2003-373286	20030224
PRIORITY APPLN. INFO.:			US 2002-359495P	P 20020225
			US 2003-373286	A2 20030224
OTHER SOURCE(S):	MARPAT 141:140424			
GI				



AB Title compds. of formula I, II, and III [wherein B = (un)substituted cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; C = (hetero)aryl (un)substituted with 1-3 R₂; or BC = (un)substituted bicyclic heterocycle; R₁ = H, OH, cycloalkyl, NH₂, or (un)substituted alkyl, alkoxy, or alkenyl; R₂ = independently H, NH₂, NO₂, CN, halo, or (un)substituted alkyl; with provisos; and pharmaceutically acceptable salts thereof] were prepared as antibacterial agents. Examples include syntheses and biol. data for 91 compds. For instance, benzyl 3-fluoro-4-(4-morpholinyl)phenylcarbamate was stirred with BuLi in THF at -78° for 30 min. Cycloaddn. with potassium (2R)-glycidate gave the 2-oxo-5-oxazolidinecarboxylic acid, which was amidated using oxalyl chloride and ammonium to afford (R)-(-)-IV. Compds. of the invention inhibited growth of *Staphylococcus aureus* with MIC values ranging from 0.5 µg/mL to 16 µg/mL. Thus, I, II, and III and their pharmaceutical compns. are useful for the treatment of microbial infections.

IT 725263-12-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(oprepn. of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as antibacterial agents)

RN 725263-12-7 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro[1]benzoxepino[4,5-d]isoxazol-8-yl)-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<10804389>



IT 725263-08-1P 725263-09-2P 725263-10-5P
725263-11-6P 725263-13-8P 725263-17-2P
725263-18-3P 725263-19-4P 725263-20-7P
725263-21-8P 725263-25-2P 725263-26-3P
725263-27-4P 725263-28-5P 725263-29-6P
725263-30-9P 725263-34-3P 725263-35-4P
725263-40-1P 725263-41-2P 725263-45-6P
725263-46-7P 725263-52-5P 725263-53-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as antibacterial agents)

RN 725263-08-1 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725263-09-2 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 725263-10-5 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-11-6 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro[1]benzoxepino[4,5-d]isoxazol-8-yl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725263-13-8 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro[1]benzoxepino[4,5-d]isoxazol-8-yl)-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

<10804389>


Absolute stereochemistry.



RN 725263-17-2 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4,5-dihydro-3-(5-isoxazolyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-18-3 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4,5-dihydro-3-(5-isoxazolyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725263-19-4 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4,5-dihydro-3-(5-isoxazolyl)-1H-

<10804389>

[1]benzoxepino[5,4-c]pyrazol-8-yl]-N-ethyl-2-oxo-, (5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-20-7 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[7-fluoro-4,5-dihydro-3-(5-isoxazolyl)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-, (5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-21-8 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[7-fluoro-4,5-dihydro-3-(5-isoxazolyl)-1H-[1]benzoxepino[4,5-d]isoxazol-8-yl]-2-oxo-, (5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<10804389>

RN 725263-25-2 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4,5-dihydro-3-(methylamino)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-26-3 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4,5-dihydro-3-(methylamino)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725263-27-4 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4,5-dihydro-3-(methylamino)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 725263-28-5 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro-3-methoxy-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-29-6 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro-3-methoxy-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725263-30-9 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(4,5-dihydro-3-methoxy-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

<10804389>


Absolute stereochemistry.



RN 725263-34-3 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(3-ethyl-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-35-4 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(3-ethyl-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725263-40-1 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(3-ethyl-7-fluoro-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

<10804389>


Absolute stereochemistry.



RN 725263-41-2 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(3-ethyl-10-fluoro-4,5-dihydro-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-45-6 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-(7-fluoro-4,5-dihydro-3-methoxy-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725263-46-7 CAPLUS

<10804389>

CN 5-Oxazolidinecarboxamide, 3-(10-fluoro-4,5-dihydro-3-methoxy-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl)-N-methyl-2-oxo-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-52-5 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[7-fluoro-4,5-dihydro-3-(methylamino)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-2-oxo-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725263-53-6 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[10-fluoro-4,5-dihydro-3-(methylamino)-1H-[1]benzoxepino[5,4-c]pyrazol-8-yl]-N-methyl-2-oxo-, (5R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:575073 CAPLUS
 DOCUMENT NUMBER: 137:140512
 TITLE: Preparation of benzoheterocyclyloxazolidinones as
 antibacterial agents.
 INVENTOR(S): Johnson, Paul D.; Aristoff, Paul A.; Poel, Toni-Jo;
 Thomasco, Lisa M.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059115	A1	20020801	WO 2001-US42944	20011114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421583	AA	20020801	CA 2001-2421583	20011114
US 2002133021	A1	20020919	US 2001-992660	20011114
EP 1337530	A1	20030827	EP 2001-997007	20011114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517929	T2	20040617	JP 2002-559417	20011114
US 2004176609	A1	20040909	US 2004-804389	20040319
US 2004186293	A1	20040923	US 2004-804380	20040319
PRIORITY APPLN. INFO.:			US 2000-249550P	P 20001117
			US 2001-992660	A3 20011114
			WO 2001-US42944	W 20011114
OTHER SOURCE(S):		MARPAT 137:140512		
GI				

<10804389>



AB Title compds. [I; Y = NHC(:W)R1, OZ, SZ, NHZ; X = O, NR3, S, SO, SO2, S(O)(NR4); W = O, S; R1 = H, alkyl, cycloalkyl, alkoxy, alkylthio, amino; R2 = H, halo, alkyl; R3 = H, alkyl, aryl, Z, etc.; R4 = H, alkyl; Z = (substituted) (aromatic) heterocyclyl; with provisos], were prepared Thus, N-[[[(5S)-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-5-oxazolidinyl]methyl]acetamide (preparation given) and NaHCO3 in THF were treated with MeO2CCl with vigorous stirring. H2O was added and the mixture was stirred 1 h to give Me (-)-6-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate. The latter showed a min. inhibitory concentration of 1 µg/mL against Streptococcus pneumoniae SPNE9912.

IT 444587-46-6P 444587-47-7P 444587-48-8P
444587-49-9P 444587-50-2P 444587-51-3P
444587-52-4P 444587-53-5P 444587-54-6P
444587-55-7P 444587-84-2P 444587-85-3P
444587-86-4P 444587-87-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoheterocyclyloxazolidinones as antibacterial agents)

RN 444587-46-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-47-7 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


<10804389>



RN 444587-48-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-49-9 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 444587-50-2 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


<10804389>



RN 444587-51-3 CAPLUS

CN Ethanethioamide, N-[[(5S) -3- (3,4-dihydro-1H-2-benzopyran-7-yl) -2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 444587-52-4 CAPLUS

CN Acetamide, N-[[(5S) -3- (3,4-dihydro-1H-2-benzothiopyran-7-yl) -2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-53-5 CAPLUS

CN Ethanethioamide, N-[[(5S) -3- (3,4-dihydro-1H-2-benzothiopyran-7-yl) -2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


<10804389>



RN 444587-54-6 CAPLUS

CN Ethanethioamide, N-[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 444587-55-7 CAPLUS

CN Acetamide, N-[[(5S)-3-(3,4-dihydro-2-oxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444587-84-2 CAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 444587-85-3 CAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444587-86-4 CAPLUS

CN Ethanethioamide, N-[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444587-87-5 CAPLUS

CN Ethanethioamide, N-[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<10804389>



IT 444588-02-7P 444588-04-9P 444588-08-3P

444588-35-6P 444588-36-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoheterocyclyloxazolidinones as antibacterial agents)

RN 444588-02-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444588-04-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444588-08-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


<10804389>



RN 444588-35-6 CAPLUS

CN Carbamic acid, [[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444588-36-7 CAPLUS

CN Carbamic acid, [[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STM

ACCESSION NUMBER: 1999:77555 CAPLUS

DOCUMENT NUMBER: 130:139335




TITLE: Preparation of tricyclically substituted oxazolidinones as bactericides

INVENTOR(S): Bartel, Stephan; Guarnieri, Walter; Riedl, Bernd; Habich, Dieter; Stolle, Andreas; Ruppelt, Martin; Raddatz, Siegfried; Rosentreter, Ulrich; Wild, Hanno; Endermann, Rainer; Kroll, Hein-peter

<10804389>

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; et al.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903846	A1	19990128	WO 1998-EP4252	19980708
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
DE 19730847	A1	19990128	DE 1997-19730847	19970718
AU 9884417	A1	19990210	AU 1998-84417	19980708
ZA 9806360	A	19990127	ZA 1998-6360	19980717
PRIORITY APPLN. INFO.:			DE 1997-19730847	A 19970718
			WO 1998-EP4252	W 19980708
OTHER SOURCE(S):	MARPAT 130:139335			
GI				



AB Title compds. [I; R1= N3, OH, OMe, OSO2Me, NH2, NHCOCH3, etc.; E = O, S, CO, SO, SO2, NC2H5, etc.; A, A1, A2, A3 are independently CH, N, with no more than one N; L and M are independently H, OH, CO, CN, NO2, CHO, etc.; dotted bonds = one single bond to I and the other single bond to a H] are prepared as antibacterial medicaments. Thus, compound II was prepared from cycloaddn. of 2-benzoyloxycarbonylamino fluorene and (R)-2,3-epoxypropyl butanoate in the presence of Bu lithium in hexane.

IT 220058-39-9P 220058-40-2P 220058-41-3P

<10804389>


220058-47-9P 220058-55-9P 220058-56-0P
220058-57-1P 220058-63-9P 220058-70-8P
220058-71-9P 220058-72-0P 220058-78-6P
220058-85-5P 220058-86-6P 220058-87-7P
220058-93-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclically substituted oxazolidinones as bactericides)

RN 220058-39-9 CAPLUS

CN 2-Oxazolidinone, 3-(3-dibenzofuranyl)-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220058-40-2 CAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[8-(1E)-1-pentenyl-3-dibenzofuranyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 220058-41-3 CAPLUS

CN 2-Oxazolidinone, 3-(8-acetyl-3-dibenzofuranyl)-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220058-47-9 CAPLUS

CN 2-Oxazolidinone, 3-(3-dibenzothienyl)-5-(hydroxymethyl)-, (5R)- (9CI) (CA

<10804389>

INDEX NAME)


Absolute stereochemistry.



RN 220058-55-9 CAPLUS

CN 2-Oxazolidinone, 3-(3-dibenzofuranyl)-5-[[methanesulfonyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220058-56-0 CAPLUS

CN 2-Oxazolidinone, 5-[[methanesulfonyl]oxy]methyl]-3-[8-(1E)-1-pentenyl-3-dibenzofuranyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 220058-57-1 CAPLUS

CN 2-Oxazolidinone, 3-(8-acetyl-3-dibenzofuranyl)-5-[[methanesulfonyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 220058-63-9 CAPLUS

CN 2-Oxazolidinone, 3-(3-dibenzothienyl)-5-[[methanesulfonyl]oxy]methyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220058-70-8 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(3-dibenzofuran-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220058-71-9 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[8-(1E)-1-pentenyl-3-dibenzofuran-2-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


<10804389>



RN 220058-72-0 CAPLUS

CN 2-Oxazolidinone, 3-(8-acetyl-3-dibenzofuranyl)-5-(azidomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220058-78-6 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(3-dibenzothienyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220058-85-5 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(3-dibenzofuranyl)-, monohydrochloride, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<10804389>




● HCl

RN 220058-86-6 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[8-(1E)-1-pentenyl-3-dibenzofuranyl]-, monohydrochloride, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● HCl

RN 220058-87-7 CAPLUS

CN 2-Oxazolidinone, 3-(8-acetyl-3-dibenzofuranyl)-5-(aminomethyl)-, monohydrochloride, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 220058-93-5 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(3-dibenzothienyl)-, monohydrochloride, (5S)-(9CI) (CA INDEX NAME)

<10804389>

Absolute stereochemistry.



● HCl


IT 220059-12-1P 220059-13-2P 220059-14-3P
220059-15-4P 220059-16-5P 220059-17-6P
220059-18-7P 220059-19-8P 220059-20-1P
220059-21-2P 220059-24-5P 220059-38-1P
220059-39-2P 220059-40-5P 220059-41-6P
220059-60-9P 220059-61-0P 220059-62-1P
220059-63-2P 220059-64-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of tricyclically substituted oxazolidinones as bactericides)

RN 220059-12-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-13-2 CAPLUS

CN Propanamide, N-[[[(5S)-3-(3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




<10804389>

RN 220059-14-3 CAPLUS

CN Carbamic acid, [[[5S)-3-(3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-15-4 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(5S)-3-(3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220059-16-5 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[8-(1E)-1-pentenyl-3-dibenzofuranyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 220059-17-6 CAPLUS

CN Propanamide, N-[[[(5S)-2-oxo-3-[8-(1E)-1-pentenyl-3-dibenzofuranyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


<10804389>



RN 220059-18-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-(8-acetyl-3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-19-8 CAPLUS

CN Propanamide, N-[[[(5S)-3-(8-acetyl-3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220059-20-1 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(5S)-3-(8-acetyl-3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 220059-21-2 CAPLUS

CN Carbamic acid, [[(5S)-3-(8-acetyl-3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-24-5 CAPLUS

CN Urea, [[(5S)-3-(3-dibenzofuranyl)-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 220059-38-1 CAPLUS

CN Propanamide, N-[[[(5S)-3-(3-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 220059-39-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-(3-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-40-5 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(5S)-3-(3-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-41-6 CAPLUS

CN Carbamic acid, [[[(5S)-3-(3-dibenzothienyl)-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<10804389>

RN 220059-60-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-(5,5-dioxido-3-dibenzothiienyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-61-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-benzofuro[2,3-b]pyridin-7-yl-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-62-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-benzofuro[3,2-c]pyridin-7-yl-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220059-63-2 CAPLUS

CN Carbamic acid, [[[(5S)-3-benzofuro[3,2-c]pyridin-7-yl-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<10804389>



RN 220059-64-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-benzofuro[2,3-c]pyridin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
25.15	186.75

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.65	-3.65

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 08:38:09 ON 07 MAR 2005